Severity, distribution and postoperative therapy are not predictors of return to work in western performance horses with stifle chondromalacia.
Authors: Esselman Angie M, Johnson Sherry A, Hague Brent A, Frisbie David D
Journal: Veterinary surgery : VS
Summary
# Editorial Summary: Stifle Chondromalacia and Return to Work in Western Performance Horses Researchers at Colorado State University conducted a retrospective review of 34 western performance horses that underwent arthroscopic diagnosis of stifle chondromalacia to determine whether lesion severity, anatomical distribution, or postoperative intra-articular therapy (bone marrow-derived mesenchymal stem cells, equine amniotic allograft, or no treatment) predicted successful return to athletic performance. Contrary to conventional clinical assumptions, neither the surgical grade of chondromalacia (slight through marked) nor its distribution pattern (focal versus diffuse) showed statistically significant associations with horses resuming work, nor did the choice of postoperative intra-articular therapy influence outcomes. Encouragingly, 74% of horses returned to some level of performance, though only 44% achieved their previous competitive level—a substantially more favourable prognosis than previously reported in the literature. These findings suggest that clinicians should counsel owners cautiously about apparent lesion severity during arthroscopy, as the visible cartilage damage may not dictate functional recovery, and should reconsider expensive intra-articular biological therapies as essential interventions for this particular pathology. The results underscore the importance of individual horse factors—perhaps rehabilitation intensity, training methods, or intrinsic healing capacity—in determining stifle chondromalacia outcomes, warranting future prospective investigation into these variables.
Read the full abstract on PubMed
Practical Takeaways
- •Don't let the grade of chondromalacia on arthroscopy alone determine your prognosis—most horses (74%) can return to some work regardless of severity or distribution
- •Choice of postoperative injection therapy (stem cells, amniotic product, or conservative management) does not significantly impact return-to-work outcomes, so focus on appropriate rehabilitation and work progression instead
- •Counsel owners realistically: while three-quarters of horses resume work, only 44% return to their exact previous level, so manage expectations about performance demands
Key Findings
- •Chondromalacia severity grade (slight, mild, moderate, marked) showed no significant association with return to athletic performance (p=0.54)
- •Focal versus diffuse distribution of chondromalacia did not significantly predict return to work (p=0.40)
- •Postoperative intra-articular therapy type (bone marrow-derived mesenchymal stem cells, amniotic allograft, or none) had no association with return to athletic work (p=0.53)
- •74% of horses returned to some level of athletic work, but only 44% returned to their previous level of performance